Idasanutlin

Drug Profile

Idasanutlin

Alternative Names: RG 7388; RO 5503781

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Mayo Clinic; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; University of Glasgow
  • Class Aminobenzoic acids; Antineoplastics; Pyrrolidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Follicular lymphoma; Multiple myeloma; Prostate cancer
  • Phase I Cancer; Essential thrombocythaemia; Polycythaemia vera; Solid tumours

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in Hungary (IV) (NCT02828930)
  • 01 Aug 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in Hungary (PO, tablet and capsule) (NCT02828930)
  • 27 Jul 2016 Phase-I development is ongoing for Cancer in Acute-myeloid-leukaemia (Combination therapy, Monotherapy) in Canada (NCT01773408)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top